At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AVDL Avadel Pharmaceuticals plc
Market Closed 01-23 16:00:00 EST
21.50
-0.03
-0.14%
盘后21.50
+0.000.00%
17:14 EST
High21.55Low21.50Vol576.23K
Open21.53D1 Closing21.53Amplitude0.21%
Mkt Cap2.11BTradable Cap1.73BTotal Shares98.15M
T/O12.41MT/O Rate0.71%Tradable Shares80.64M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Avadel Pharmaceuticals- Ireland High Court Sets Hearing for Avadel's Scheme on Alkermes for Feb 10, 2026 - SEC Filing
THOMSON REUTERS  ·  01-20
Avadel Pharmaceuticals- Ireland High Court Sets Hearing for Avadel's Scheme on Alkermes for Feb 10, 2026 - SEC Filing
Irish Court Sets Date to Sanction Avadel Pharmaceuticals Acquisition by Alkermes
Reuters  ·  01-20
Irish Court Sets Date to Sanction Avadel Pharmaceuticals Acquisition by Alkermes
Avadel Shareholders Approve Acquisition by Alkermes
Reuters  ·  01-13
Avadel Shareholders Approve Acquisition by Alkermes
Avadel Pharmaceuticals Announces That Avadel Shareholders Approve the Proposed Acquisition by Alkermes
THOMSON REUTERS  ·  01-13
Avadel Pharmaceuticals Announces That Avadel Shareholders Approve the Proposed Acquisition by Alkermes
Assessing Avadel Pharmaceuticals (AVDL) Valuation After a Strong 1-Year Share Price Rally
Simply Wall St.  ·  2025-12-19
Assessing Avadel Pharmaceuticals (AVDL) Valuation After a Strong 1-Year Share Price Rally
Avadel Pharmaceuticals Completes Enrollment in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia
Reuters  ·  2025-12-18
Avadel Pharmaceuticals Completes Enrollment in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 Revitalyz™ Trial in Idiopathic Hypersomnia
THOMSON REUTERS  ·  2025-12-18
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 Revitalyz™ Trial in Idiopathic Hypersomnia
Avadel Pharmaceuticals Plc - Data Expected in Q2 2026
THOMSON REUTERS  ·  2025-12-18
Avadel Pharmaceuticals Plc - Data Expected in Q2 2026
HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes
Reuters  ·  2025-12-10
HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes
Press Release: Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
Dow Jones  ·  2025-12-04
Press Release: Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
Avadel Pharmaceuticals Plc - Scheme Meeting and Egm Scheduled for January 12, 2026
THOMSON REUTERS  ·  2025-12-02
Avadel Pharmaceuticals Plc - Scheme Meeting and Egm Scheduled for January 12, 2026
BUZZ-H Lundbeck steps down from takeover for Avadel, shares rise 3%
Reuters  ·  2025-11-27
BUZZ-H Lundbeck steps down from takeover for Avadel, shares rise 3%
Jefferies expects Avadel-Alkermes deal to close
TIPRANKS  ·  2025-11-27
Jefferies expects Avadel-Alkermes deal to close
Avadel Pharmaceuticals (AVDL) Gets a Hold from Wells Fargo
TIPRANKS  ·  2025-11-20
Avadel Pharmaceuticals (AVDL) Gets a Hold from Wells Fargo
Deals of the day-Mergers and acquisitions
Reuters  ·  2025-11-20
Deals of the day-Mergers and acquisitions
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)
TIPRANKS  ·  2025-11-19
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)
BRIEF-H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options
Reuters  ·  2025-11-19
BRIEF-H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options
H Lundbeck a/S: Noted That Our Offer for Acquiring Avadel No Longer Is Considered Superior by Their Board, We Are Currently Considering Our Options
THOMSON REUTERS  ·  2025-11-19
H Lundbeck a/S: Noted That Our Offer for Acquiring Avadel No Longer Is Considered Superior by Their Board, We Are Currently Considering Our Options
Avadel Pharmaceuticals (AVDL) Receives a Hold from H.C. Wainwright
TIPRANKS  ·  2025-11-19
Avadel Pharmaceuticals (AVDL) Receives a Hold from H.C. Wainwright
Avadel Pharmaceuticals Shares up 1.5% Premarket After Alkermes Raises Offer to Buy Co
THOMSON REUTERS  ·  2025-11-19
Avadel Pharmaceuticals Shares up 1.5% Premarket After Alkermes Raises Offer to Buy Co

Introduction

Company Name.
Avadel Pharmaceuticals plc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Issue price:
--